Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

4.04
-0.0300-0.74%
Pre-market: 3.91-0.1281-3.17%04:53 EDT
Volume:68.47K
Turnover:280.12K
Market Cap:2.21M
PE:-0.04
High:4.30
Open:4.06
Low:3.95
Close:4.07
52wk High:179.19
52wk Low:3.45
Shares:547.78K
Float Shares:547.42K
Volume Ratio:0.01
T/O Rate:12.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-102.4151
EPS(LYR):-337.9329
ROE:-705.71%
ROA:-127.92%
PB:0.44
PE(LYR):-0.01

Loading ...

Artelo Biosciences - Receives Uspto Notice of Allowance for Art27.13 Formulation Patent

THOMSON REUTERS
·
Aug 17

Artelo Biosciences - Patent Protection for Art27.13 Expected Through 2041

THOMSON REUTERS
·
Aug 17

Artelo Biosciences Gets USPTO Notice of Allowance for Art27.13 Formulation Patent Application

Reuters
·
Aug 17

Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives

Reuters
·
Aug 14

Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 14

Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises

Reuters
·
Aug 14

CV Sciences Q2 Sales Fall on Regulatory Pressure

Reuters
·
Aug 14

Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY

Benzinga Earnings
·
Aug 13

Artelo Biosciences Q2 EPS USD -0.89

THOMSON REUTERS
·
Aug 13

Press Release: Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Dow Jones
·
Aug 13

Artelo Biosciences Q2 FY26 Net Loss Narrows 24.65% to USD 2.43 Million

Reuters
·
Aug 13

Artelo Biosciences Doses First Patient in Phase 2 Glaucoma Trial of Art27.13

Reuters
·
Aug 10

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating Art27.13 for Treatment of Glaucoma

THOMSON REUTERS
·
Aug 10

Artelo Biosciences - Initial Dream Study Results Anticipated in Q4 2026

THOMSON REUTERS
·
Aug 10

South Korea's Stock Market Now Mirrors Nasdaq, Raising Diversification Fears Among Investors

Deep News
·
Jul 28

Artelo Analysis Finds Low-dose OTC CBD Products Miss Therapeutic Efficacy Across 50-plus Studies

Reuters
·
Jul 22

Artelo Biosciences announces new ART26.12 data

TIPRANKS
·
Jul 16

Artelo Says Preclinical Osteoarthritis Study Shows Art26.12 Matches Naproxen Pain Relief with Less Gastric Damage

Reuters
·
Jul 16

Artelo Biosciences - to Begin Clinical Multiple Ascending Dose Study of Art26.12 in Q4

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting Art26.12 as a Potential First-in-class New Therapy for Chronic Pain Conditions

THOMSON REUTERS
·
Jul 16